Stanford’s SyntheMol platform generated designs and synthesis pathways for six novel antibiotics in under nine hours. Traditional pharmaceutical companies have explored only 0.0000001% of possible drug molecules across their entire history. Meanwhile, AI-driven platforms achieve 80-90% success rates in Phase I trials while traditional drug development suffers 90% failure rates despite $83 billion inRead more











